8-K filings and company releases

Company news

2 articles on Viking Therapeutics.

Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.

Download on the App StoreGet it on Google Play

Free on iOS and Android

VKTX articles

Newest first, 25 to a page
  1. Nov 15, 2026 · Company release

    Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026

    In an exploratory analysis of its Phase 2 VENTURE trial, 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo.

    Company release
  2. Nov 9, 2026 · Company release

    Viking Therapeutics to present two VK2735 posters at ObesityWeek 2026

    The posters cover baseline characteristics from the Phase 3 VANQUISH-2 trial and the effects of VK2735 in the Phase 2 VENTURE study.

    Company release

How these are written

  • The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
  • The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
  • The date: the day the company filed the 8-K or published the release.
  • Not investment advice. An article reports what the company disclosed; it is not a view on the stock.